USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
A Cocaine Kingpin and the Rise of Drug Violence in Europe
Rupert Murdoch’s Succession Drama Goes to Court
Why 33,000 Boeing Workers Walked Off the Job
Fraudulent Online Returns Cost Retailers Billions
Red, White and Who? A Swing-State Debate
The Fight Over U.S. Steel and the Community Caught in the Middle
Testosterone Clinics Sell Virility. Side Effects Sometimes Included.
Your New Hire May Be a North Korean Spy
How Betting on U.S. Politics Is Getting Big
Hot, Dry and Booming: A Texas Climate Case Study
Red, White and Who? How Abortion Plays For Trump and Harris
A Fed Insider on the Looming Rate Cut
The Rise of the Tween Shopper
What's Behind the Arrest of the Telegram CEO?
For Kamala Harris, a Big Interview and a Narrow Lead
Private Equity Finally Can Get a Piece of the NFL
Why China Is Risking a Trade War
Lending Elon Musk Money Was A Very Bad Bet
Etsy: Big Commerce or Crafters' Community?
Hope, Unity (and Some Nerves) at the DNC
Create your
podcast in
minutes
It is Free
WSJ Tech News Briefing
WSJ What’s News
WSJ Opinion: Potomac Watch
WSJ Your Money Briefing
The Indicator from Planet Money